Vitamin versus tumor: How niacin might help fight glioblastoma

Blue purple pink 3d rendering of brain
Scientists found that niacin, also known as vitamin B3, could revitalize the brain's immune cells to help tackle glioblastoma. (monsitj/iStock/Getty Images Plus)

Glioblastomas are hard to treat in part because the brain’s immune cells are suppressed and unable to launch an attack against tumors. A research team at the University of Calgary in Canada found that a common vitamin might help solve the problem.

In a study published in Science Translational Medicine, the researchers showed that niacin, also known as vitamin B3, can stimulate immune cells that are otherwise compromised by brain tumors. Treating mice with niacin increased the number of immune cells in the tumor, reduced tumor size and extended survival, the team reported.

The prognosis for glioblastoma remains poor partly because brain tumor initiating cells (BTICs)—which are stem cell-like progenitor cells in the tumors—are resistant to chemoradiotherapy treatments such as commonly used temozolomide (TMZ).

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

When brain tumors first develop, immune-boosting cells such as macrophages and microglia may try to combat them. But BTICs tend to turn these immune cells into promoters of tumor growth instead. Therefore, drugs that can bolster immune cells could hold promise as GBM treatments.

The University of Calgary team screened a library of 1,040 compounds for anti-tumor activity that hinged on immune reactions. Niacin emerged as a promising candidate.

The researchers started by testing niacin in immune cell cultures. They found that the vitamin increased the amount of several cytokines such as TNF-alpha in monocytes—a type of white blood cell that can differentiate into macrophages—as well as in macrophages and microglia.

Niacin-treated monocytes reduced BTIC growth in cell lines, the team found. Further analysis suggested that niacin achieved that by promoting the expression of the protein IFN-alpha14. In another cell culture experiment, the researchers found that niacin reactivated monocytes isolated from glioblastoma patients, restoring their ability to suppress the growth of BTICs.

To further validate their findings, the Calgary team implanted patient-derived BTICs into mice and treated them with niacin. They observed reduced tumor volume and prolonged survival. Combining niacin with TMZ produced even better results. The combo prolonged survival in a mouse model by at least fivefold and performed better than solo niacin.

RELATED: Killing brain tumors with CAR-Ts built with scorpion venom

The niacin study is the latest example of scientists turning to unconventional sources for inspiration in treating glioblastoma. A team at City of Hope recently designed CAR-T cells based on a toxin called chlorotoxin found in scorpion venom. Scientists at the University of Pennsylvania showed that targeting the Wnt/beta-catenin signaling pathway to block the abnormal growth of blood vessels feeding tumors could overcome TMZ resistance in glioblastoma. Another group at Cedars-Sinai Medical Center used a polymer-based system to deliver checkpoint inhibitors of CTLA-4 or PD-1 so that the therapy can cross the blood-brain barrier to reach glioblastoma tumors.

As for niacin, it has already been safely used in humans at high doses to treat atherosclerotic coronary disease and dyslipidemias. Now, with its immune-stimulatory effect, the vitamin “could be rapidly translated into clinical use as an adjunctive treatment for patients with GBM,” the University of Calgary team wrote in the study.

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.